Lori Muffly
YOU?
Author Swipe
View article: Superior long-term outcomes with fludarabine and melphalan reduced intensity regimen in older AML/MDS patients undergoing allogeneic stem cell transplantation: An analysis of CIBMTR data
Superior long-term outcomes with fludarabine and melphalan reduced intensity regimen in older AML/MDS patients undergoing allogeneic stem cell transplantation: An analysis of CIBMTR data Open
Introduction: Reduced intensity and non-myeloablative (RIC/NMA) conditioning regimens are routinely utilized in allogeneic hematopoietic cell transplantation (alloHCT) for older patients with AML/MDS. However, the efficacy of different con…
View article: Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT
Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT Open
Introduction Whether allogeneic hematopoietic cell transplantation (HCT) is curative for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) harboring TP53 mutations (TP53m) is under debate. TP53m often co-occur with complex (CK…
View article: Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)
Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM) Open
Background: Bridging therapy (BT) is critical for delivering chimeric antigen receptor T (CAR-T) therapy in patients with RRMM as manufacturing times vary from 4-8 weeks and patients require interim disease control. We evaluated the impact…
View article: A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01)
A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01) Open
Background and significance Relapsed/Refractory (R/R) T-ALL/LBL remains a significant therapeutic challenge due to lack of effective therapies. CTD402, is a novel universal (U) anti-CD7 CAR-T therapy, with T cell receptor, CD7, and human l…
View article: Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world
Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world Open
Introduction: Brexucabtagene autoleucel (Brexu-cel) is a CD19-targeted chimeric antigen receptor (CAR-)T cell therapy approved for treatment of relapsed/refractory (r/r) B-ALL. Brexu-cel's approval was founded on data from the ZUMA-3 trial…
View article: CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity
CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity Open
Introduction CD19-directed CAR-T cells (CAR19) induce responses in relapsed/refractory (R/R) mantle cell (MCL) and follicular lymphoma (FL). However, CAR19 in MCL is associated with high rates of ICANS (between 9-31% grade 3+ in pivotal tr…
View article: Evaluation of commercially available chimeric antigen receptor (CAR) detection reagents for monitoring of CAR T-cell (CAR T) expansion and persistence in patients (pts) treated with obecabtagene autoleucel (obe-cel)
Evaluation of commercially available chimeric antigen receptor (CAR) detection reagents for monitoring of CAR T-cell (CAR T) expansion and persistence in patients (pts) treated with obecabtagene autoleucel (obe-cel) Open
Background: Obe-cel is a CD19-directed autologous CAR T therapy with a fast off-rate binding domain and a 4-1BB-ζ co-stimulatory domain designed to improve persistence and minimize immunotoxicity (Roddie et al. NEJM 2024). Increasing evide…
View article: Pre-treatment CD19 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL
Pre-treatment CD19 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL Open
Introduction: CD19 directed CAR T cell therapies, such as axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), are standard treatments for relapsed/refractory large B-cell lymphomas (LBCL); despite high initial respon…
View article: CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias
CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias Open
CD19-directed chimeric antigen receptor T-cell therapy (CAR19) improves survival in patients with relapsed/refractory large B-cell lymphoma (rrLBCL) compared to immunochemotherapy with intent for autologous hematopoietic cell transplantati…
View article: CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia Open
CAR-T treatment for B-cell acute lymphoblastic leukemia (ALL) induces high initial response rates, but most patients relapse. Low disease burden (often defined as < 5% blasts in the bone marrow) is associated with better outcomes. CAR-H…
View article: The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia Open
View article: Impact of transplant conditioning, <i>NPM1</i> mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia
Impact of transplant conditioning, <i>NPM1</i> mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia Open
We conducted a post hoc analysis of data from Blood and Marrow Transplant Clinical Trials Network 1506 (MORPHO), a randomized trial of gilteritinib vs placebo as posttransplantation maintenance for patients with FLT3-ITD–mutated acute myel…
View article: Real-world performance of the CALGB 10403 regimen in young adults in the United States
Real-world performance of the CALGB 10403 regimen in young adults in the United States Open
View article: Fatal recurrence of IEC-HS after autologous stem cell boost in patients receiving BCMA-CAR T-cell therapy
Fatal recurrence of IEC-HS after autologous stem cell boost in patients receiving BCMA-CAR T-cell therapy Open
[Figure: see text]
View article: Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement Open
Patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) with central nervous system (CNS) involvement (CNS B-ALL) have poor outcomes and were frequently excluded from CD19-targeting chimeric antigen receptor (CA…
View article: Humanizing CAR T-cell therapy in B-ALL
Humanizing CAR T-cell therapy in B-ALL Open
View article: Figure S8 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Figure S8 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Comparative analysis of CAR22 transduction rate, vector copy number (VCN) and T cell subset in CAR22 products between patients who experienced disease progression (PD) within 90 days versus more than 90 days after CAR19 therapy (A) Patient…
View article: Table S6 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Table S6 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
CAR22 product release criteria
View article: Table S7 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Table S7 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Key reagents and resources
View article: Figure S4 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Figure S4 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Comparative analysis of Comparative analysis of T cell subsets of CD4/CD8 enrichment material during CAR22 manufacturing process. (A) CD4+ and (B) CD8+ T cells.
View article: Figure S1 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Figure S1 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Hemogram analysis prior to leukapheresis for CAR22
View article: Figure S11 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Figure S11 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
CAR22 construction
View article: Table S3 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Table S3 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Comparison of CAR19 transgene level, CAR22 product characteristic and cell kinetics across different CAR19 co-stimulatory domain
View article: Figure S6 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Figure S6 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Comparative analysis of exhaustion markers expression of CD4/CD8 enrichment material during CAR22 manufacturing process Expression of exhaustion markers, including CD39, lymphocyte-activation gene 3 (LAG-3), programmed cell death protein 1…
View article: Table S4 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Table S4 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Comparison of CRS, ICANS, and IEC-HS between different leukapheresis interval groups, CAR19 transgene level, and CAR22 product transduction rate cut off by median
View article: Figure S9 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Figure S9 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Cytopenia within 28 days following CAR22 infusion in early and late groups. (A) The nadir white blood cell count, hemoglobin levela and platelet count were comparable between early and late groups. (B) Similar administration of filgrastim …
View article: Table S5 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Table S5 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
CAR T-cell surveillance methods and time points of the two cohorts
View article: Data from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Data from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Patients with large B-cell lymphoma that progresses after anti–CD19 chimeric antigen receptor (CAR) T-cell (CAR19) therapy have poor outcomes. Subsequent CAR T-cell therapy shows promise, but the impact of residual CAR19 and early relapse …
View article: Figure S10 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Figure S10 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Quantifiable CAR19 transgene levels in leukapheresis material and CAR22 products, and their correlation with CAR22 complete response (CR) rate and survival outcomes. (A) The CR rate is similar between patients with and without quantifiable…
View article: Table S1 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Table S1 from Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Open
Cohort 2: Patient demographics upon receiving CAR19 or CAR22 therapies